pre-IPO PHARMA

COMPANY OVERVIEW

At Geneos Therapeutics, we believe that personalized therapies are the future of cancer treatment. Our passion is to develop personalized therapies to unleash the most powerful force against cancer – the patients' own immune system. Our approach using our GT-EPIC™ platform is to target unique neoantigens (abnormal mutations produced by cancer cells) from individual patient tumors to develop novel and personalized treatments for cancer.


LOCATION


THERAPEUTIC AREAS


WEBSITE

None


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


Sep 27, 2023

Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million


Aug 22, 2023

Geneos Therapeutics Announces Eight of 34 Patients to Achieve Complete Response, Complete Molecular Response, or, Secondary Resectability in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer


Jul 28, 2023

Geneos Therapeutics Nominated for 2023 Prix Galien USA Startup Award


Apr 12, 2023

Geneos Therapeutics Secures $5 Million in Series A3 Financing


Dec 14, 2022

Geneos Therapeutics Announces Another Complete Response in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer


For More Press Releases


Google Analytics Alternative